Michelle Dipp

Michelle Dipp, M.D., Ph.D., (b ca. 1976) Co-Founder and Managing Partner at Biospring Partners and has over a decade of private equity and venture capital expertise in life sciences. She currently serves on the Board of Abzena.[1]

Prior to launching Biospring Partners, Michelle was a Managing Director at General Atlantic, a global growth equity firm based in New York. While at General Atlantic, Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee. Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore.

Michelle currently serves on the Trustee Advisory Board for Beth Israel Deaconess Medical Center.,[2] Advisory Board for the Women’s Foundation of Boston,[3] and the Board of Directors for Life Science Cares.[4] In addition, she is a member of the Rockefeller University Council;[5] a member of the Advisory Council for the American Museum of Natural History; a Co-Founding Member of the Bowman Fund, Brasenose College Boat Club, Oxford University; and a member of the World Economic Forum Young Global Leaders.[6][7]

Background

Michelle Dipp was raised in El Paso, Texas and earned her MD (MBBS) in Bachelor of Medicine, Bachelor of Surgery in 2001 and PhD in Physiology and Pharmacology in 2005 from the University of Oxford; her dissertation was on pulmonary hypertension.[8]

Career

After graduating from Oxford, Dipp went to work for Wellcome Trust in its private equity division.[9] Wellcome was an early investor in Sirtris Pharmaceuticals,[10] which was founded in 2004 by scientist David Sinclair, venture capitalist Christoph Westphal, serial entrepreneur Andrew Perlman, Richard Aldrich, Richard Pops, and Paul Schimmel.[11][12] The company focused on resveratrol formulations and derivatives as activators of the SIRT1 enzyme.[11][13] The company's initial product was called SRT501, and was a formulation of resveratrol.[14] Westphal and Sinclair aggressively marketed investment in the company as an anti-aging opportunity, which was controversial[11][15] but effective; the company raised $100 million in 2006.[15]

Westphal recruited Dipp to join Sirtris in 2005 and she became the Vice President of Corporate Development.[10] Sirtris went public in 2007 and was subsequently purchased and made a subsidiary of GlaxoSmithKline in 2008 for $720 million; Westphal remained CEO of the subsidiary and was also appointed senior vice president of GSK's Center of Excellence for External Drug Discovery (CEEDD).[16]

In 2008, Dipp worked with Westphal, Aldrich, and Alexey Margolin to found Alnara Pharmaceuticals, which was created to develop ways to formulate biopharmaceuticals so they could be taken by mouth, instead of by injection.[10][17]

In February 2010, Dipp, Westphal, and Aldrich formed a new venture fund called Longwood Founders Fund.[18][19] Prior to launching Longwood Founders Fund, Dipp was the senior vice president and head of the Centre of Excellence for External Drug Discovery (CEEDD) at GlaxoSmithKline (GSK).

In April 2010, Westphal stepped down as CEO of Sirtris. Dipp took over as senior vice president of CEEDD; this made her the youngest senior VP in all of the world's top ten pharmaceutical companies.[10][20]

In August 2010, the Longwood team co-founded VeraStem by providing seed funding and office space its offices, with Westphal serving as CEO and chairman of the board; Verastem aimed to isolate cancer stem cells and then discover drugs that would selectively kill them.[21][22] The company held its IPO in 2012.[22]

GSK/Sirtris terminated development of SRT501 in late 2010.[23][24] In 2013 GSK shut down Sirtris and its development candidates were absorbed into GSK, where research and development continued.[16][25][26]

In January 2015 Longwood and Dipp helped found Flex Pharma[27] Later that year she was named as one of Fortune Magazine's "40 under 40"[28] and was also named one of 187 "Young Global Leaders" by the World Economic Forum.[6]

In November 2016 Dipp and Longwood helped launch Axial Biotherapeutics, which aimed to modulate the gut-brain axis to treat neurological diseases; its strategy at launch was open with company considering developing drugs to influence the gut microbiota as well as probiotics; Dipp took a board seat.[29]

Dipp was appointed to the governing board of the Biotechnology Industry Organization’s Emerging Companies section in December 2013. By the end of 2013 she and Westphal had joined the approximately 100 overseers of the Boston Symphony Orchestra; BSO overseers advise the Board of Trustees on various matters including fundraising.[30][31] In October 2014 she joined the board of directors of Beth Israel Deaconess Medical Center.[2] By 2015 she had joined the board of directors of the New England Venture Capital Association.[32]

In October 2017 Dipp became the Managing Director at General Atlantic,[33][34] a global growth equity firm based in New York. While at General Atlantic Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee. Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI[35] and Immunocore.

References
  1. Louch, Laura Cooper and William (2020-07-28). "Biospring Partners Backs Drug Developer and Manufacturer Abzena". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-07-28.
  2. "Press Release: Beth Israel Deaconess Medical Center Names Six to Board of Directors". Beth Israel Deaconess Medical Center. 2 October 2014.
  3. "Women's Foundation of Boston | Advisory Board". Women's Foundation of Boston. Retrieved 2020-02-19.
  4. "Life Sciences Cares Advisory Board". Retrieved 2020-02-19.
  5. "Rockefeller University Council". Support our science. Retrieved 2020-02-19.
  6. Aikman, David (17 March 2015). "Press Release: Meet the 2015 class of Young Global Leaders". World Economic Forum.
  7. "World Economic Forum: Leadership Page". World Economic Forum. Retrieved 2020-10-30.
  8. Gray, Robert (June 13, 2016). "El Paso's biotech wunderkind Michelle Dipp". El Paso Inc.
  9. McBride, Ryan. "Dr. Michelle Dipp - Women in Biotech 2012". FierceBiotech.
  10. McBride, Ryan (22 April 2010). "Sirtris Vet Michelle Dipp Takes Over Key Role at Glaxo as Westphal Returns to VC". Xconomy.
  11. Couzin, J (27 February 2004). "Scientific community. Aging research's family feud". Science. 303 (5662): 1276–9. doi:10.1126/science.303.5662.1276. PMID 14988530.
  12. "Sirtris S-1 Registration for IPO". Sirtris via SEC Edgar. March 1, 2007.
  13. Wade, Nicholas (17 August 2009). "Tests Begin on Drugs That May Slow Aging". The New York Times.
  14. McBride, Ryan (12 August 2010). "Former Sirtris Execs' Nonprofit Starts Selling Resveratrol with Potential Anti-Aging Effects Online". Xconomy.
  15. Davies, Kevin (April 26, 2010). "Christoph Westphal Dishes on Aging and Pharmageddon". www.bio-itworld.com.
  16. Carroll, John; McBride, Ryan (Mar 12, 2013). "UPDATED: GSK moves to shutter Sirtris' Cambridge office, integrate R&D". FierceBiotech.
  17. Timmerman, Luke (30 October 2008). "Alnara Pharmaceuticals Aims to Make Biotech Drugs You Can Swallow, And That Go Right Where They Belong". Xconomy.
  18. Timmerman, Luke (12 February 2010). "Sirtris Founders Build New Venture Capital Fund, Keep Mum". Xconomy.
  19. McBride, Ryan (6 January 2011). "Rich Aldrich, Biotech Powerbroker, Breaks Silence on New $87M Longwood Founders Fund". Xconomy.
  20. McBride, Ryan (21 April 2010). "Christoph Westphal Resigns as Sirtris CEO, Takes Over Glaxo's SR One Venture Arm". Xconomy.
  21. "S-1, Amendment 3". Verastem via SEC EDGAR. 2012-01-13.
  22. Fidler, Ben (6 June 2013). "Verastem Switches CEOs as Westphal Steps Into Chairman Role". Xconomy.
  23. Wade, Nicholas (10 January 2011). "Doubt on Anti-Aging Molecule as Resveratrol Trial Is Halted". The New York Times.
  24. "GlaxoSmithKline Halts All Further Development Of Resveratrol Drug SRT501". Myeloma Beacon. November 30, 2010.
  25. "GSK absorbs controversial 'longevity' company : News blog". Nature Blog.
  26. Timmerman, Luke (12 March 2013). "GlaxoSmithKline Shuts Down Sirtris, Five Years After $720M Buyout". Xconomy.
  27. Fidler, Ben (28 January 2015). "Investors Line up For Westphal as Muscle Cramp Startup Upsizes IPO". Xconomy.
  28. Roberts, Daniel; Gallagher, Leigh (24 September 2015). "Michelle Dipp". Fortune.
  29. Fidler, Ben (30 November 2016). "With $19M, Axial Becomes Latest Startup to Target Gut-Brain Connection". Xconomy.
  30. "Boston Symphony Orchestra, Inc. Annual Report 2012–13" (PDF). Boston Symphony Orchestra, Inc. 2014.
  31. "Press Release: Boston Symphony Orchestra Announces New Board Leadership and 2014 Class of Trustees and Overseers". BSO. July 15, 2014.
  32. "The NEVCA Board". New England Venture Capital Association. Archived from the original on 27 September 2015.
  33. "Dr. Michelle Dipp Joins General Atlantic as Managing Director". General Atlantic. Retrieved 2020-02-24.
  34. "Michelle Dipp Joins General Atlantic as Managing Director". FinSMEs.com. 2017-10-12. Retrieved 2020-10-30.
  35. "PathAI Secures $60M in Series B Funding Led by General Atlantic and Existing Investor General Catalyst". www.businesswire.com. 2019-04-17. Retrieved 2020-02-24.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.